A Systematic Review of the Clinical and Cost-Effectiveness of Memantine in Patients with Moderately Severe to Severe Alzheimer’s Disease

被引:0
|
作者
Joanna Kirby
Colin Green
Emma Loveman
Andrew Clegg
Joanna Picot
Andrea Takeda
Elizabeth Payne
机构
[1] University of Southampton,Southampton Health Technology Assessments Centre (SHTAC)
来源
Drugs & Aging | 2006年 / 23卷
关键词
Memantine; Rivastigmine; Galantamine; Transit Probability; Personal Social Service;
D O I
暂无
中图分类号
学科分类号
摘要
Alzheimer’s disease (AD) is the most common form of dementia and is characterised by a worsening of cognition, functional ability, and behaviour and mood. The objective of this study was to review the clinical and cost-effectiveness of memantine for the treatment of patients with moderately severe to severe AD. To achieve this, a systematic search and review of the clinical and cost effectiveness literature for memantine was undertaken. The literature search covered the period from the inception of MEDLINE, Cochrane Library, EMBASE and other electronic databases until July 2004. The search included randomised controlled trials (RCTs) and full economic evaluations that assessed the use of memantine in patients with moderately severe to severe AD.
引用
收藏
页码:227 / 240
页数:13
相关论文
共 50 条
  • [1] A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer's disease
    Kirby, Joanna
    Green, Colin
    Loveman, Ennna
    Clegg, Andrew
    Picot, Joanna
    Takeda, Andrea
    Payne, Elizabeth
    [J]. DRUGS & AGING, 2006, 23 (03) : 227 - 240
  • [2] Cost effectiveness of memantine in the treatment of moderately severe and severe Alzheimer's disease in Spain
    Antonanzas, F
    Badenas, J
    François, C
    Guilhaume, C
    [J]. VALUE IN HEALTH, 2003, 6 (06) : 765 - 765
  • [3] Cost effectiveness of memantine in moderately severe to severe Alzheimer's disease -: A Markov model in Finland
    François, C
    Sintonen, H
    Sulkava, R
    Rive, B
    [J]. CLINICAL DRUG INVESTIGATION, 2004, 24 (07) : 373 - 384
  • [4] Cost-effectiveness of memantine in moderate and severe Alzheimer's disease in Norway
    Rive, B.
    Aarsland, D.
    Grishchenko, M.
    Cochran, J.
    Lamure, M.
    Toumi, M.
    [J]. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2012, 27 (06) : 573 - 582
  • [5] COST-EFFECTIVENESS OF MEMANTINE IN THE TREATMENT OF MODERATE TO SEVERE ALZHEIMER'S DISEASE IN NORWAY
    Toumi, M.
    Lamure, M.
    Grishchenko, M.
    Cochran, J.
    Rive, B.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A370 - A370
  • [6] Cost Effectiveness of Memantine in Moderately Severe to Severe Alzheimer’s DiseaseA Markov Model in Finland
    Clément François
    Harri Sintonen
    Raimo Sulkava
    Benoît Rive
    [J]. Clinical Drug Investigation, 2004, 24 : 373 - 384
  • [7] Clinical improvement in Alzheimer's disease patients with moderately severe and severe dementia treated with Akatinol memantine
    Gavrilova, SI
    Jarikov, GA
    Kalyn, YB
    Kolykhalov, IV
    Selezneva, ND
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S381 - S381
  • [8] Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands
    Hoogveldt, Bart
    Rive, Benoit
    Severens, Johan
    Maman, Khaled
    Guilhaume, Chantal
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2011, 7 : 313 - 317
  • [9] Modeling the Cost-Effectiveness of Galantamine for Mild to Moderately Severe Alzheimer's Disease in Korea
    Suh, Guk-Hee
    [J]. VALUE IN HEALTH, 2009, 12 : S49 - S54
  • [10] Treatment benefits of memantine in moderately severe to severe Alzheimer's disease patients with behavioural symptoms
    Wilcock, G.
    Ballard, C.
    Cooper, J.
    Loft, H.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 : 72 - 72